ELVN Q3 2023 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$21M

EPS (Diluted)

$-0.51

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$274M

Total Liabilities

$12M

Stockholders' Equity

$262M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$24M	-$11M	-121.8%
Net Income	-$21M	-$11M	-96.8%